Takeaway
- Men with type 2 diabetes mellitus (T2DM) who are diagnosed with prostate cancer (PCa), particularly those treated with gonadotropin-releasing hormone (GnRH) agonists may require 2 additional consecutive escalations in T2DM treatment.
Why this matters
- T2DM has been found to be associated with increased risk for several solid malignancies.
- Androgen deprivation therapy, a gold standard treatment for advanced PCa showed increased risk for T2DM.
Study design
- Cohort study of 16,778 men (PCa, n=962; no PCa, n=15,816) with T2DM from Prostate Cancer database Sweden Traject between 2005 and 2014.
- Patients were followed for a median of 2.5 years.
- Funding: Swedish Research Council and others.
Key results
- As an initial treatment, 9692 men were under diet control and 6373 men received metformin.
- No association between PCa diagnosis and risk for a single treatment escalation was identified (HR, 0.99; 95% CI, 0.87-1.13).
- PCa diagnosis was found to be associated with a significantly increased risk of receiving 2 consecutive T2DM treatment escalations (HR, 1.75; 95% CI, 1.38-2.22).
- Increase in T2DM treatment was significantly higher for men taking GnRH agonists (HR, 3.08; 95% CI, 2.14-4.40).
Limitations
- Repeated measures of HbA1c levels were not available.
References
References
